Istiratumab (MM-141) is an experimental

monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodie ...

for the treatment of cancer. It is a bispecific antibody targeting

IGF-1R The insulin-like growth factor 1 (IGF-1) receptor is a protein found on the surface of human cells. It is a transmembrane receptor that is activated by a hormone called insulin-like growth factor 1 (IGF-1) and by a related hormone called IGF-2. I ...

and

ErbB3 Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ''ERBB3'' gene. ErbB3 is a member of the EGFR family, epidermal growth factor re ...

. It is in development by

Merrimack Pharmaceuticals Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer. Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a l ...

(In the US) and was awarded

orphan drug An orphan drug is a medication, pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by th ...

status for pancreatic cancer.

References

Experimental cancer drugs Monoclonal antibodies Orphan drugs {{monoclonals for tumors